Pharmacoepidemiology and drug safety | 2021

Bias of time-varying exposure effects due to time-varying covariate measurement strategies.

 
 

Abstract


PURPOSE\nIn studies of effects of time-varying drug exposures, adequate adjustment for time-varying covariates is often necessary to properly control for confounding. However, the granularity of the available covariate data may not be sufficiently fine, for example when covariates are measured for participants only when their exposure levels change.\n\n\nMETHODS\nTo illustrate the impact of choices regarding the frequency of measuring time-varying covariates, we simulated data for a large target trial and for large observational studies, varying in covariate measurement design. Covariates were measured never, on a fixed-interval basis, or each time the exposure level switched. For the analysis, it was assumed that covariates remain constant in periods of no measurement. Cumulative survival probabilities for continuous exposure and non-exposure were estimated using inverse probability weighting to adjust for time-varying confounding, with special emphasis on the difference between five-year event risks.\n\n\nRESULTS\nWith monthly covariate measurements, estimates based on observational data coincided with trial-based estimates, with five-year risk differences being zero. Without measurement of baseline or post-baseline covariates, this risk difference was estimated to be 49% based on the available observational data. With measurements on a fixed-interval basis only, five-year risk differences deviated from the null, to 29% for six-monthly measurements, and with magnitude increasing up to 35% as the interval length increased. Risk difference estimates diverged from the null to as low as -18% when covariates were measured depending on exposure level switching.\n\n\nCONCLUSION\nOur simulations highlight the need for careful consideration of time-varying covariates in designing studies on time-varying exposures. We caution against implementing designs with long intervals between measurements. The maximum length required will depend on the rates at which treatments and covariates change, with higher rates requiring shorter measurement intervals.

Volume None
Pages None
DOI 10.1002/pds.5328
Language English
Journal Pharmacoepidemiology and drug safety

Full Text